ABSTRACT
Personality disorders affect between 5% and 10% of the general population (Ellison & Shader, 2003). Among those with eating disorders, the explicit prevalence of Axis II disorders remains unknown (see Sansone, Levitt, & Sansone, 2005), although these types of comorbidities appear common (Sansone et al., 2005). Personality disorders may be more prevalent among patients with eating disorders in inpatient settings and residential and tertiary-care facilities compared with those in outpatient settings. In these more intensive settings, patients tend to have more complex psychiatric comorbidity. Although these patients, who are challenging to treat, may seem to be the very population in most need of pharmacological intervention, studies of medications specifically designed for patients with eating disorders and personality disorders are virtually nonexistent.
